United States Patent 9,283,233 (Ulipristal Acetate) Claim Scope and US Patent Landscape for Post‑Coital Contraception (72–120 Hours)
What does US Patent 9,283,233 claim for ulipristal acetate contraception between 72 and 120 hours?
Core claim scope is method-of-use for oral ulipristal acetate, 30 mg, administered in the 72–120 hour window after unprotected intercourse.
The patent is directed to a specific timing-defined dosing regimen, not to manufacture, not to a new chemical entity, and not to a new delivery device.
Claim 1: timing + dose + indication (method-of-use)
Claim 1 recites:
- “A method for contraception”
- “administering 30 mg of ulipristal acetate”
- “to a woman more than 72 hours and up to 120 hours after an unprotected intercourse”
Practical boundaries created by Claim 1
- Timing is essential. Infringement requires administration occurring after 72 hours but not later than 120 hours from the unprotected intercourse event.
- Dose is essential. The claim requires 30 mg ulipristal acetate (not 15 mg, not 10 mg, not “up to 30 mg,” not weight-based).
- Indication framing is essential. Although contraception is the method’s stated purpose, the operational use is still tied to the timing window and dosage.
- Act is “administering.” Direct administration by a prescriber, clinic, or pharmacy under a regimen can satisfy “administering,” while supply of an approved drug without the timing-specific method can still implicate induced use depending on litigation theory.
Dependent claims: route, dosage form, release profile
Claim 2 limits Claim 1 to:
Claim 3 limits Claim 2 to:
- ulipristal acetate is administered as an oral solid dosage form.
Claim 4 limits Claim 3 to:
- the oral solid dosage form is a tablet.
Claim 5 limits Claim 1 to:
- immediate-release formulation.
How dependent claims narrow infringement
- If an alleged infringer administers ulipristal acetate in the window with a non-oral route (eg, buccal/sublingual) or a non-solid oral form (eg, suspension), they avoid Claim 2/3/4.
- If the product is not immediate-release (eg, extended-release), Claim 5 does not read.
- If the timing falls at or below 72 hours or above 120 hours, Claim 1 does not read.
What elements are most likely to drive infringement in US 9,283,233?
The most litigable triplet is: (1) timing, (2) 30 mg dose, (3) oral immediate-release tablet use.
Timing proof (72–120 hours)
Evidence typically comes from:
- patient intake forms and time stamps,
- prescribing instructions,
- pharmacy counseling records,
- and post-label adverse event reporting, if used in discovery.
Because “more than 72 hours and up to 120 hours” is a bright-line range, timing disputes are common:
- “more than 72” excludes exactly 72.0 hours.
- “up to 120” includes any time ≤120.0 hours.
Dose proof (30 mg)
The dose requirement can be satisfied if the regimen is 30 mg delivered as the claimed ulipristal acetate amount, even if packaged as a single tablet or multiple tablets that sum to 30 mg (the literal reading turns on what counts as “30 mg of ulipristal acetate” delivered at administration). For litigation, dosage strength and number of units matter.
Form and release proof (claims 2–5)
- Oral and solid form are usually established by product monograph and compendial description.
- “tablet” is product-specific.
- “immediate-release” is formulation-specific; generic applicants often design for bioequivalence of immediate-release; extended-release would avoid Claim 5.
How does US 9,283,233 relate to known ulipristal acetate emergency contraception products (EllaOne/Ella)?
The patent aligns with the extended emergency contraception window for ulipristal acetate. In the US context, ulipristal acetate emergency contraception is marketed under branded naming (commonly “ella” in the US). The claims here are not about the general use of ulipristal acetate but are pinned to the expanded window and a specific 30 mg immediate-release oral tablet method.
What a generic must do to avoid literal infringement
A literal noninfringement strategy would be to change at least one of the essential claim elements:
- do not administer at >72 to ≤120 hours (route around the timing window), or
- do not dose at 30 mg, or
- use a non-oral route, or
- use a non-solid oral form, or
- use a non-tablet solid, or
- use a non-immediate-release formulation.
In practical generic scenarios, route/form/release generally match the originator’s approved product to achieve regulatory approval and bioequivalence. That makes the timing window the primary commercial differentiation point, but marketing differentiation is difficult because the indication is what FDA labels and patients need.
What US exclusivity and regulatory timing issues are implicated by this method-of-use claim?
A method-of-use claim does not necessarily block approval, but it can drive Paragraph IV litigation risk and launch timing restrictions through Hatch-Waxman settlements.
Key operational points for a generic/biosimilar-style pathway for small molecules:
- FDA approval can proceed if the applicant navigates Orange Book-listed patents via Paragraph IV certification and litigation timing.
- A method-of-use claim can be asserted against “use” rather than manufacturing, creating settlement pressure even if the generic product is already approved.
Orange Book status and certification mechanics (what matters for 9,283,233)
For any branded reference product with an NDA in the Orange Book, US 9,283,233 would be listed for a described method of use. The generic applicant would likely need to address it via:
- Paragraph I/II/III/IV depending on patent status and expiration.
- If the patent is listed and not expired, Paragraph IV is the pathway to seek earlier effective entry while litigation is ongoing.
The patent’s enforceability (validity and infringement) often determines settlement terms and “design-around” needs.
How many claims does 9,283,233 cover in total, and what is the legal risk profile of each?
With the five claims provided, risk is layered:
| Claim |
Key limitation |
Coverage breadth |
Infringement risk if generic matches originator product |
| 1 |
30 mg ulipristal acetate, contraception, administered >72 and ≤120 hours after unprotected intercourse |
Broadest (timing + dose + indication) |
High, if labeled use supports the regimen |
| 2 |
Claim 1 + oral administration |
Narrower by route |
High if generic is oral (likely) |
| 3 |
Claim 2 + oral solid dosage form |
Narrower by dosage form |
High if generic is solid (likely) |
| 4 |
Claim 3 + tablet |
Narrower by unit form |
High if generic is tablet (likely) |
| 5 |
Claim 1 + immediate-release formulation |
Narrower by release profile |
High if generic is immediate-release (likely) |
Net: The claim set is consistent with standard originator generic replication. That increases infringement exposure and makes validity challenges the primary path to avoid injunction or settlement-driven delay.
What would be the strongest design-around for a competitor to reduce infringement of 9,283,233?
Based on the claim language supplied, the most credible design-arounds are:
-
Timing-labeled divergence
If a competitor can only market a regimen outside “>72 to ≤120 hours,” it avoids Claim 1. Practically, FDA labeling and clinical evidence are required.
-
Dose divergence
If a competitor’s supported regimen is not 30 mg, it avoids Claim 1. That usually requires new clinical data and can limit regulatory adoption.
-
Release or dosage-form divergence
Avoid “immediate-release” (Claim 5) or “tablet” (Claim 4) by using a different formulation form factor. That typically conflicts with the need to match bioequivalence and the known originator product.
In most small-molecule generic disputes, the design-around burden is high; hence settlement leverage concentrates around this exact method-of-use window.
What is the patent landscape around ulipristal acetate emergency contraception in the US for 72–120 hour use?
The landscape for emergency contraception programs generally includes multiple strata:
- Method-of-use claims covering timing windows (like 9,283,233).
- Formulation claims covering tablet composition, excipients, crystallinity/polymorph, and stability.
- Manufacturing process claims for producing ulipristal acetate or the dosage form.
- Regulatory and Orange Book listings that tie specific patents to the NDA and label.
For risk assessment, the key question is whether other patents also claim overlapping elements:
- the same 72–120 hour window,
- the same 30 mg dose,
- the same oral immediate-release tablet format.
When multiple patents cover the same label region, settlement often addresses the entire cluster rather than a single patent.
What patent expiration and litigation timing factors govern launch risk for US 9,283,233?
US 9,283,233 is a US utility patent with a fixed expiration tied to its earliest effective filing date and potential PTA/PTE. For launch timing, two timelines matter:
- Statutory expiration (utility patent term and any adjustments).
- Exclusivity/settlement end dates that may effectively delay generic entry even after legal expiration.
Method-of-use patents often drive settlements that set an “entry date” based on the controlling listed patent(s), not necessarily the moment one specific patent expires.
How to evaluate “controlling” patents
In practice, the controlling patent is the one(s) that:
- are asserted or likely asserted,
- are listed in the Orange Book,
- have the strongest infringement readability,
- and withstand typical invalidity challenges.
With claims that track standard use of ulipristal emergency contraception, 9,283,233 can be a controlling patent in that cluster.
Which generic entry scenarios create the highest risk under 9,283,233?
Highest risk scenario: a generic ulipristal acetate 30 mg immediate-release oral tablet that is FDA-labeled for emergency contraception use within the “>72 to ≤120 hours” window.
Lower risk scenarios
- A generic product that cannot be labeled (or is not promoted) for the 72–120 hour window.
- A formulation that is non-tablet or not immediate-release (rare for standard generic development).
- A product with a different supported dose.
How does 9,283,233 compare with other potential emergency contraception IP strategies?
For emergency contraception, competitors commonly rely on one of three claim themes:
- Timing-window method-of-use (like this patent).
- Formulation-specific improvements (stability, bioavailability, polymorph).
- Alternative dosing regimens (different dose, different schedule, sometimes different active).
Against timing-window claims, generic companies typically litigate validity rather than attempting labeling/timing divergence. Against formulation claims, generic companies often litigate composition-specific patents or attempt formulation design.
What does claim construction likely do to scope in US litigation involving 9,283,233?
Claim terms likely receive ordinary meaning in context:
- “more than 72 hours” sets a strict boundary.
- “up to 120 hours” sets a ceiling.
- “administering” is action-based; it does not require a specific device.
- “tablet” limits physical dosage form.
- “immediate-release” generally requires that the formulation is not designed for delayed/extended release.
The narrower the dependent claims, the more the core dispute becomes Claim 1, because a generic that is standard immediate-release oral tablets typically reads most dependent features.
Key Takeaways
- US 9,283,233 claim 1 is a tight method-of-use: 30 mg oral ulipristal acetate given >72 and ≤120 hours after unprotected intercourse for contraception.
- Dependent claims enforce additional narrowing: oral (Claim 2), oral solid (Claim 3), tablet (Claim 4), and immediate-release (Claim 5).
- The infringement risk profile is high for a generic that is a 30 mg immediate-release oral tablet labeled for the expanded window, because it tracks typical originator-use patterns.
- The core litigation leverage is the timing window plus dose, not chemistry or manufacturing.
FAQs
1) Does US 9,283,233 require that the unprotected intercourse be the same event used to calculate hours?
Claim 1 ties administration to “after an unprotected intercourse,” meaning the dosing window is calculated from the patient’s unprotected intercourse timing as the triggering event.
2) Would a 30 mg ulipristal acetate product that is not immediate-release avoid claim 5?
Yes. Claim 5 requires “immediate-release.” Non-immediate-release formulations fall outside that dependent claim.
3) Can a competitor avoid infringement by using a different route while keeping the same timing and dose?
Yes for claims 2–4 (oral/tablet limits). Claim 1 still requires administering 30 mg ulipristal acetate within the timing window, but the route limitations are only in dependent claims.
4) What is the biggest challenge in designing around the “>72 to ≤120 hours” window?
Regulatory labeling and evidence. If the product is clinically and label-supported for the expanded window, it will likely be used in exactly the claimed timing range.
5) Is this patent likely to block generic product approval, or does it mainly drive litigation/settlement risk?
Method-of-use patents generally drive litigation and settlement and can constrain “use” rather than necessarily preventing FDA approval, but they commonly affect launch timing through Paragraph IV practice.
References
- United States Patent 9,283,233.
